[suzierose]

Videos from Managing Myeloma

by suzierose on Thu May 31, 2012 9:07 pm

"So, Dr. Palumbo, in 2012, who are the best clinical candidates for maintenance-based therapy, and is there a clinical scenario that best fits for maintenance therapy? For example, should all patients who undergo autologous transplant receive maintenance-based therapy, or should all patients receive maintenance therapy after induction in the nontransplant setting?"

http://www.managingmyeloma.com/index.php?option=com_content&view=article&catid=142&id=706&Itemid=134

[suzierose]

Re: Videos from Managing Myeloma

by suzierose on Thu May 31, 2012 9:26 pm

FAQ...how long should patients remain on maintenance?

http://www.managingmyeloma.com/index.php?option=com_content&view=article&id=700&catid=83&Itemid=102

[suzierose]

Re: Videos from Managing Myeloma

by suzierose on Thu May 31, 2012 9:32 pm

"Dr. Ruben Niesvizky discusses the community-based phase IIIb UPFRONT study in elderly patients exploring three different bortezomib containing induction therapies (BD, BTD, MPB) followed by bortezomib maintenance therapy which seeks to address questions such as whether an alkylating agent is necessary and whether three-drug combinations are better than two. Dr. Niesvizky also provides an update of the BiRD regimen (clarithromycin, lenalidomide, dexamethasone); his insights regarding the UK based MRC Myeloma IX study of zoledronic acid vs. clodronate, and the randomized phase II trial of elotuzumab (anti-CS1/HuLuc63) plus lenalidomide and low-dose dexamethasone in relapsed/refractory patients."

http://www.managingmyeloma.com/index.php?option=com_content&view=article&id=607&Itemid=86

[suzierose]

Re: Videos from Managing Myeloma

by suzierose on Thu May 31, 2012 9:46 pm

"Dr. Rafael Fonseca discusses research regarding gene expression profiling (GEP) of multiple myeloma (multiple myeloma) plasma cells obtained from multiple myeloma patient volunteers in various stages of the disease with the goal of identifying the most significant gene expression indices and signatures relevant to multiple myeloma risk-stratification in order to better predict who has more aggressive disease. Dr. Fonseca also discusses next generation agents for relapsed refractory disease, including the proteasome inhibitor carfilzomib, and the immunomodulatory drug (IMiD) pomalidomide, as well as the report of the survival of elderly multiple myeloma patients from the 30-year experience of ECOG."

http://www.managingmyeloma.com/index.php?option=com_content&view=article&id=608&Itemid=86

[suzierose]

Re: Videos from Managing Myeloma

by suzierose on Thu May 31, 2012 10:09 pm

Great Institutional Debates...

experts clash on when/how to treat ( UPenn vs. Cornell)...Stadtmauer vs Niesvizky

"Today we are going to about the institutional differences and many similarities between the two institutions. So Ruben, how do you figure out when a patient with myeloma should have treatment?....

The BiRD regimen has become very famous from your institution (Cornell). So we agree also that there definitely is clear evidence now that the conventional chemotherapies that we have used in the past, the VAD regimen, the melphalan and prednisone regimen, do seem to be inferior to the novel agents. The current regimens that we use most commonly are the combination of lenalidomide and dexamethasone or bortezomib and dexamethasone, though one of the most exciting aspects of this most recent American Society of Hematology meeting was the use of these now triple therapies where we incorporate both the immunomodulatory medicine and the proteasome inhibitor along with dexamethasone and the responses that we are seeing are anywhere from 80 to 100% of the patients responding to initial therapy."

http://www.managingmyeloma.com/index.php?option=com_content&view=article&id=263&catid=44&Itemid=92&Itemid=92